Credit Suisse Downgrades Shire to Neutral (SHP)
Shire (LON:SHP) was downgraded by analysts at Credit Suisse to a “neutral” rating in a research report issued to clients and investors on Thursday, American Banking and Market News reports. They currently have a GBX 2,600 ($41.71) price objective on the stock. Credit Suisse’s price target would indicate a potential upside of 8.92% from the stock’s previous close.
Shire (LON:SHP) opened at 2386.00 on Thursday. Shire has a 1-year low of GBX 1682.00 and a 1-year high of GBX 2602.00. The stock has a 50-day moving average of GBX 2432.08 and a 200-day moving average of GBX 2167.18. The company’s market cap is £13.113 billion.
SHP has been the subject of a number of other recent research reports. Analysts at Jefferies Group raised their price target on shares of Shire from GBX 2,700 ($43.32) to GBX 2,900 ($46.53) in a research note to investors on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Shire in a research note to investors on Thursday. They now have a GBX 2,660 ($42.68) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Shire in a research note to investors on Tuesday. They now have a GBX 3,000 ($48.13) price target on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of GBX 2,035.02 ($32.65).
Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.